23 May 2025

💉Final Determination on Biomedix IV Product Country of Origin

Notice of Issuance of Final Determination Concerning Biomedix Selec-3 Multiple Drop Intravenous Product

Summary

This document provides notice that U.S. Customs and Border Protection (CBP) has issued a final determination concerning the country of origin of the Biomedix Selec-3 Multiple Drop Intravenous Product. Based upon the facts presented, CBP has concluded that the subject IV products, under two of five scenarios, would be the product of a foreign country or instrumentality designated pursuant to title III of the Trade Agreements Act of 1979, as amended; in three of the scenarios, the last substantial transformation occurs in the United States.

Agencies

  • Homeland Security Department
  • U.S. Customs and Border Protection

Business Impact ?

$$$ - High

The text involves substantial regulatory requirements regarding the country of origin for medical products, specifically the Biomedix Selec-3 IV Product, which impacts compliance with trade agreements and government procurement processes. This has significant implications for businesses reliant on U.S. Customs and Border Protection regulations regarding sourcing and potential market access.

View Related Items ?

< >